Pembrolizumab (Keytruda®) accepted for restricted use within NHS Scotland for renal cell carcinoma
Pembrolizumab intravenous infusion in combination with axitinib, is approved for the first-line treatment of advanced renal cell carcinoma in adults, subject to a two-year clinical stopping rule.
Source:
Scottish Medicines Consortium